ClinicalTrials.gg
Not yet recruitingNCT07825012Updated Sep 17, 2026

External Validation of the FedHist Dynamic Early Warning Model for Mortality Risk in Critically Ill Patients: A Prospective Multicenter Study

An observational study in ICU, sponsored by Southeast University, China. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Southeast University, China · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
23,579
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess how accurately FedHist, an artificial intelligence model, predicts the risk of death in critically ill patients. Patients in intensive care units (ICUs) can become worse quickly. Updating risk estimates as new clinical information becomes available may help identify patients at higher risk. FedHist uses routinely collected clinical information to estimate a patient's risk of dying in the ICU within the next 24 hours. These estimates are updated every 6 hours.

This study will evaluate FedHist prospectively across several hospitals. The model will be integrated into hospital clinical information systems, and its predictions will be compared with observed patient outcomes. The study aims to determine whether FedHist provides accurate predictions across hospitals with different patient populations and clinical practices.

Read the detailed description

Critically ill patients can deteriorate rapidly, creating a need for timely and repeated assessment of mortality risk. Conventional severity assessments, including the Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores, provide clinically useful information. However, risk assessments based on data from defined assessment periods may not fully capture evolving clinical trajectories. Models that incorporate longitudinal clinical data may support more frequent assessment of short-term mortality risk.

Artificial intelligence offers opportunities to integrate clinical information collected over time for dynamic risk prediction. However, models developed using data from a single center or database may perform differently in other settings. Differences in patient characteristics, disease severity, measurement frequency, and clinical workflows can affect predictive performance. Privacy requirements, data governance policies, and institutional control over data also limit the pooling of patient records for conventional centralized model development.

FedHist was developed using a federated learning framework incorporating electronic health records from more than 250,000 critically ill patients across five countries and regions. This framework enabled collaborative model development while raw patient data remained at the contributing institutions. FedHist generates an updated estimate of the risk of ICU death within the next 24 hours at 6-hour intervals.

Previous evaluations showed a macro-averaged area under the receiver operating characteristic curve (AUROC) of 0.893 in internal validation. AUROCs were 0.881 in the NWICU external validation cohort and 0.961 in the prospective CDIC cohort. FedHist outperformed the corresponding locally trained models. When only 10% of the development data at each site were used, its performance approached or exceeded that of local models trained on the full development datasets. These findings support further prospective evaluation following integration into routine clinical information systems across multiple hospitals.

This prospective multicenter study will externally validate the previously developed FedHist model in participating ICUs. The model will be integrated into local clinical information systems to generate risk estimates using prospectively collected clinical data. Predictions will be compared with observed ICU outcomes to assess performance in predicting death within the subsequent 24 hours. The study will evaluate predictive performance across participating hospitals and assess the generalizability of FedHist under routine clinical conditions.

02

Conditions studied

  • ICU
03

In context

Lead sponsor

Southeast University, China is the lead sponsor of 168 studies on the registry; 45 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients admitted to the participating ICU

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admission to a participating ICU

Exclusion criteria

Exclusion Criteria:

  • Age younger than 18 years.
  • Expected ICU length of stay shorter than 24 hours.
  • Refusal to provide written .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
23,579 participants (estimated)
Patient registry
No

Interventions

  • OtherRisk of mortality

    Patients admitted to the ICU with different risk of mortality

06

What researchers measure

Primary outcomes

  1. ICU mortality

    The proportion of patients who die from any cause during the ICU stay, with follow-up capped at 90 days after ICU admission. For patients whose ICU stay exceeds 90 days, vital status at day 90 will be used to determine the mortality outcome.

    Time frame: From ICU admission to ICU discharge or 90 days after ICU admission, whichever occurs first.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07825012
Responsible party
Jianfeng Xie (Professor, Southeast University, China) — Principal investigator
First posted
Sep 17, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

hui chen
Contact
huichen.icu@gmail.com
+86-18006138640

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion